Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study

BackgroundThe objective of this study was to evaluate the efficacy and safety of gemcitabine plus cisplatin concurrent chemoradiotherapy (CCRT) in patients with nasopharyngeal carcinoma.MethodPatients with NPC were randomly assigned to the gemcitabine plus cisplatin (GP) group or fluorouracil plus cisplatin (PF) group. Primary end-point was disease-free survival (DFS); secondary endpoints: overall survival, distant metastasis-free survival (DMFS), locoregional relapse-free survival, and treatment-related adverse events.ResultsSeventy-six patients were prospectively enrolled and the median follow-up time was 41months (9-61months). Three-year DFS were similar between the GP and PF groups (73.7% vs. 60.5%, HR 0.66, 95% CI 0.30-1.44; P=0.30). Distant metastasis was the most common failure form in PF compared with GP (P=0.034). Three-year DMFS was significantly better in the GP group than PF group (89.5% vs. 71.1%, P=0.045). Grade 3-4 gastrointestinal toxicities (vomiting and diarrhea) were significantly more common in the PF group; grade 3-4 neutropenia and thrombocytopenia were more common in the GP group.ConclusionGemcitabine plus cisplatin could be used as an alternative regimen in CCRT for nasopharyngeal carcinoma.